Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
KYTX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Kyverna Therapeutics, Inc.NASDAQ: KYTX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $3.17M rose 46.7% year over year, ahead of the +34.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 17.4% from the prior quarter. Over 3 fiscal years it compounded at +121.4% a year.
Context
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +46.7% holds above the trailing-twelve-month pace of +34.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 10.08M USD
- Year-over-year change
- +20.6%
- 4-year CAGR
- +8.6%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.08M | +20.6% |
| FY2024 | 2024-12-31 | 8.36M | +276.4% |
| FY2023 | 2023-12-31 | 2.22M | +139.0% |
| FY2022 | 2022-12-31 | 929K | -87.2% |
| FY2021 | 2021-12-31 | 7.25M | — |
Stock-Based Compensation vs competitors
How KYTX compares with its peers on the latest reported figures
- KYTX's LTM Mar 2026 stock-based compensation of $11.09M is the 9th largest of the 11 companies compared; the peer median is $15.92M.
- Its year-over-year change of +34.6% is the 2nd highest of 10, against a peer median of -9.1%.
- Over three fiscal years its annual growth of +121.4% compares with a peer median of +16.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.98B | +32410.1% | +56.9% | — | |
| LTM Mar 2026 | $35.81M | +19.3% | — | 115500.0% | |
| LTM Mar 2026 | $33.74M | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $21.03M | +1.0% | +44.8% | — | |
| LTM Mar 2026 | $17.5M | -62.1% | -23.7% | — | |
| LTM Mar 2026 | $14.34M | — | -14.0% | 1556.3% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $11.29M | +31.2% | +73.3% | — |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $11.19M | -19.1% | +89.6% | — |
| LTM Mar 2026 | $11.09M | +34.6% | +121.4% | — | |
| LTM Mar 2026 | $9.12M | -45.7% | -30.1% | 23.6% | |
| LTM Mar 2026 | $6.93M | -9.1% | +16.8% | 1385.0% | |
| Peer median (excluding KYTX) | $15.92M | -9.1% | +16.8% | 1470.7% | |
Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.35M) | (28.89M) | (60.37M) | (127.48M) | (161.31M) |
| Depreciation & Amortization | 586K | 1.05M | 1.71M | 2.13M | 1.8M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.25M | 929K | 2.22M | 8.36M | 10.08M |
| Change in Working Capital | (4.49M) | (10.33M) | 3.42M | 7.86M | (1.08M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 11K | 677K | 4.08M | 736K | 543K |
| Other Working Capital | (4.5M) | (11M) | (659K) | 7.12M | (1.62M) |
| Other Non-Cash Items | 850K | 1.13M | 605K | (5.12M) | (3.21M) |
| Operating Cash Flow | (22.16M) | (36.11M) | (52.41M) | (114.25M) | (153.71M) |
| Capital Expenditures | (1.29M) | (768K) | (621K) | (2.21M) | (5K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 70K |
| Purchases of Investments | 0 | (56.5M) | (54.85M) | (490M) | (364.62M) |
| Sales of Investments | 0 | 43.17M | 46.68M | 323.64M | 398.81M |
| Other Investing Activities | 0 | 0 | 0 | 7.66M | 5.76M |
| Investing Cash Flow | (1.29M) | (14.1M) | (8.79M) | (160.9M) | 40.02M |
| Debt Repayment | (41K) | (249K) | (781K) | (956K) | 23.89M |
| Common Stock Issued | 0 | 0 | 0 | 341.17M | 117.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 30K | 175K | (1M) | (3.1M) | (144K) |
| Financing Cash Flow | 72.52M | 11.88M | 58.12M | 337.11M | 141.17M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 49.08M | (38.33M) | (3.08M) | 61.96M | 27.47M |
| Free Cash Flow | (23.44M) | (36.88M) | (53.03M) | (116.46M) | (153.72M) |
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.